. Author manuscript; available in PMC: 2013 Dec 17.

Published in final edited form as: Clin Cancer Res. 2012 Jul 3;18(18):10.1158/1078-0432.CCR-12-0912. doi: 10.1158/1078-0432.CCR-12-0912

Table 1.

Comparison of clinical characteristics of HER2 mutant patients vs other molecularly defined subsets

		HER2 (n=25)	HER2 WT (n=1359)	EGFR (n=359)	KRAS (n=495)	EML4-ALK (n=35)	BRAF (n=25)
Gender	(female/male)	17/8	862/497	260/99	326/169	19/16	17/8
Median age	(range)	64 (51–84)	66 (32–90)	66(32–90)	67 (38–86)	56 (39–78)	70 (54–79)
Median age	pts <64 / ≥66 yrs	16/9	588/771(p=0.04)	158/201	205/290 (p=0.04)	21/14	12/13
Smoking Status	(never/smoker)	17/8	340/1019 (p<0.0001)	192/167	30/465 (p<0.0001)	21/14	3/22 (p=0.0001)
Stage	(I–II / III–IV)	15 / 10	631/728	147 / 212	246 / 249	7/28 (p=0.0025)	11/14 (p=0.03)
Ethnicity	Asian /Caucasian	2/23	59/1267

p values in parentheses based on comparison with HER; only significant values are annotated